Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neisserial heparin-binding antigen (NHBA) and outer membrane vesicle (OMV) antigens are primary components of the 4CMenB vaccine, which has shown significant cross-protective efficacy against Neisseria gonorrhoeae. NHBA is a surface-exposed lipoprotein that binds heparin, a property that contributes to the bacterium's ability to resist complement-mediated killing and adhere to host epithelial cells (PubMed: 20651146). OMVs are naturally occurring blebs from the bacterial outer membrane that contain a variety of immunogenic proteins, including porins and lipoproteins, which serve to prime the host immune system (PubMed: 28754558). Due to the high degree of sequence conservation between Neisseria meningitidis and Neisseria gonorrhoeae, antibodies elicited by these antigens in the 4CMenB vaccine can recognize and target gonococcal homologs (PubMed: 30139801). This interaction leads to the recruitment of the complement system and enhanced opsonophagocytosis, effectively reducing the colonization and transmission of the gonococcus (PubMed: 35417753). As antibiotic resistance in gonorrhea becomes a global health crisis, these antigens represent a critical focus for vaccine-mediated prevention strategies.
Induction of cross-reactive bactericidal antibodies that facilitate opsonophagocytosis and complement-mediated killing of Neisseria gonorrhoeae by targeting conserved surface proteins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neisserial heparin-binding antigen (NHBA) and outer membrane vesicle (OMV) antigens (NHBA and OMV).